Discovery of antibody biomarkers for Alzheimer’s Disease

阿尔茨海默病抗体生物标志物的发现

• 批准号: 9092101
• 负责人: Thomas J. Kodadek
• 金额: $ 33.6万
• 依托单位: SCRIPPS FLORIDA
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-05-01 至 2018-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9092101
• 关键词: Affinity; Alzheimer disease detection; Alzheimer' s Disease; Antibodies; Antigens; Binding; Binding Sites; Biological Assay; Biological Markers; Biology; Blood; Blood Tests; Dementia; Development; Diagnosis; Diagnostic Sensitivity; Diagnostic Specificity; Disease; Epitopes; Generations; Goals; Immune system; Individual; Investigation; Laboratories; Lead; Libraries; Ligands; Light; Medical; Methods; Neurodegenerative Disorders; Pathology; Patients; Sampling; Serum; Source; Staging; System; Testing; Validation; Work; antigen binding; biomarker discovery; clinically relevant; combinatorial; diagnostic assay; follow-up; novel; public health relevance; research study; screening; specific biomarkers

 DESCRIPTION (provided by applicant): The discovery of serum biomarkers for Alzheimer's disease (AD) represents an enormous unmet medical need. This project will further explore the hypothesis that the adaptive immune system might react to unusual antigens produced as a result of AD pathology and as a result produce high levels of antibodies that would not be found in a normal individual. There is some evidence that this is the case. To discover these antibodies we plan to screen large libraries of bead-displayed synthetic oligomers and find compounds that retain far more antibodies from AD serum samples than from controls. These molecules would be employed as first generation "capture agents" for the AD-specific antibodies in a multiplexed Luminex-like diagnostic assay. If this R21 preliminary investigation is successful, it would set the stage for compound optimization and a much larger validation trial that could lead to an effective blood test for AD.

 描述（由申请人提供）：阿尔茨海默病 (AD) 血清生物标志物的发现代表了巨大的未满足的医疗需求，该项目将进一步探讨适应性免疫系统可能对 AD 病理产生的异常抗原做出反应的假设。结果产生了在正常个体中找不到的高水平抗体，有一些证据表明情况确实如此。更多抗体这些分子将被用作多重 Luminex 类诊断测定中 AD 特异性抗体的第一代“捕获剂”。如果 R21 初步研究成功，将为化合物奠定基础。优化和更大规模的验证试验可能会导致对 AD 进行有效的血液检测。